DORTMUND, Germany, March 17, 2026
iDEL Therapeutics announced the successful close of a €9 million seed financing round led by BiomedVC, marking its official launch and accelerating the development of a novel oncology pipeline based on direct cytosolic transfer technology. The company aims to transform cancer treatment by enabling targeted intracellular drug delivery, unlocking previously undruggable cancer targets, and improving therapeutic outcomes across multiple solid tumor indications.
Innovative Cytosolic Delivery Platform Targets Cancer Cells
At the core of iDEL Therapeutics’ innovation is its proprietary direct cytosolic transfer technology, designed to deliver therapeutic payloads directly into the cytosol of tumor cells, bypassing traditional barriers such as endosomal entrapment and intracellular degradation. This approach significantly enhances drug bioavailability, intracellular exposure, and target engagement, addressing a major limitation in current cancer therapies.
Unlike conventional delivery systems, iDEL’s platform is compatible with both small molecules and large biologics, including antibodies and nanobodies, offering broad applicability across diverse oncology targets. By preventing drug degradation and improving retention within tumor cells, the technology has the potential to increase therapeutic efficacy and expand treatment options for difficult-to-treat cancers.
The platform’s pan-cancer applicability positions it as a versatile solution capable of addressing multiple tumor types, reinforcing its value in next-generation precision oncology.
Advertisement
Seed Financing to Accelerate Pipeline Toward Clinical Trials
The €9 million funding round, supported by leading investors including BiomedVC, NRW.Venture, Gründerfonds Ruhr, and KHAN Technology Transfer Fund II, will be used to advance iDEL’s proprietary lead programs toward clinical evaluation. The company is currently developing two lead oncology candidates, leveraging its unique delivery system to improve drug targeting and anti-tumor activity.
The financing will also support expansion of preclinical proof-of-concept studies, optimization of drug candidates, and preparation for future clinical trials, marking a critical step in translating the company’s technology from research to real-world application.
Industry experts have highlighted the potential of iDEL’s approach to address longstanding challenges in oncology, including limited intracellular drug delivery and insufficient tumor retention, which often hinder treatment success. By overcoming these barriers, the company aims to enhance treatment durability and patient outcomes.
Unlocking New Opportunities in Precision Oncology Innovation
Cancer treatment continues to face significant challenges, particularly in targeting intracellular proteins and complex molecular pathways that are difficult to access using conventional therapies. iDEL Therapeutics’ platform seeks to address these challenges by enabling direct access to intracellular disease mechanisms, opening new possibilities for targeted and effective cancer therapies.
The company’s approach aligns with broader trends in the pharmaceutical industry, where there is increasing focus on precision medicine, targeted drug delivery, and innovative therapeutic platforms. By combining cutting-edge technology with strong scientific expertise, iDEL Therapeutics is positioning itself to contribute to the next wave of oncology innovation.
Furthermore, the establishment of a highly experienced leadership team with expertise in biopharma and drug development strengthens the company’s ability to navigate the complex path from preclinical research to clinical validation and commercialization.
Driving the Future of Cancer Therapeutics
The launch of iDEL Therapeutics and its successful seed financing represent a significant milestone in early-stage biotech innovation, with the potential to reshape how cancer therapies are developed and delivered. By addressing critical limitations in current treatment approaches, the company’s technology could pave the way for more effective, targeted, and durable cancer treatments.
As iDEL advances its pipeline toward clinical development, the company is expected to play a key role in expanding the boundaries of oncology therapeutics, contributing to improved outcomes for patients facing some of the most challenging forms of cancer. The initiative underscores the importance of continued investment in scientific innovation and early-stage drug development, which are essential for driving progress in the global fight against cancer.
Source: iDEL Therapeutics press release
